Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable... It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.
- Mechanism
- Curator reviewed
Perflubutane perfusion echocardiography has the potential to be a cost-effective and convenient alternative to nuclear perfusion imaging. Perflubutane is easy to use and echocardiographers in the clinical trials can be trained to use it after imaging only a few patients. Based on data from previous clinical trials, ultrasound enhanced with Perflubutane was able to image myocardial perfusion and obtain information that appears comparable to nuclear imaging. Acusphere's Phase 3 program is designed with the appropriate comparative standards to determine the value of Perflubutane perfusion echocardiography relative to nuclear perfusion imaging. These standards are coronary angiography, nuclear perfusion imaging, and patient outcome.
- Formula / weight
- C4F10 · 238.028 g/mol (avg)
- Also known as
- Decafluorobutane · Sonazoid
- Code names
- AI-700
Resolves to
KAVGMUDTWQVPDF-UHFFFAOYSA-NSMILESFC(F)(F)C(F)(F)C(F)(F)C(F)(F)FWhat you can answer from here — as of March 06, 2025
Which companies are running trials of Perflubutane, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account